U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110610) titled 'Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants' on July 01.
Brief Summary: This is a first-in-human, randomized, double-blind, placebo-controlled Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered LTG-321 in healthy male and female participants 18 to 55 years of age. The study will be conducted in New Zealand.
The study also includes a randomized, double-blind, placebo-controlled, within-participant crossover evaluation of pain tolerance using a cold pressor test in hea...